Self Help Program for Hypnotics Withdrawal in Insomniac Patients
NCT02720458 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62
Last updated 2026-05-12
Summary
Persistent insomnia has a high prevalence in French general population affecting between 15.8 % and 19 % of adults. In France, the disease is mainly managed by general practitioners (GP) who usually proposed intermediate half-life benzodiazepines and Z-drugs in first-line treatment. French Health authorities recommend restricting the consumption of both hypnotics to no more than 4 weeks, considering their potential adverse effects (memory impairment, altered sleep physiology, motor-vehicle crash), and the risk of tolerance and dependence. However, it appears that a majority of patients become chronic users. Therefore, discontinuation of benzodiazepines/Z-drugs is recommended, but it may appear as a challenge due to withdrawal symptoms and psychological factors (anticipatory anxiety, fear of rebound insomnia).
Numerous studies have shown that programs based on Cognitive-Behavioural Therapy (CBT) principles improve sleep and daily life quality leading to hypnotic taper and maintain of hypnotic abstinence in insomniac patients. Cognitive-Behavioural Therapy (CBT) is based on 4 components: sleep restriction, stimulus control, cognitive therapy and sleep hygiene education. This therapy is dependent on a therapeutic alliance between practitioner and patient. Unfortunately, there are an insufficient number of trained CBT experts especially in France.
The implementation of an internet-delivered self-help program based on time-in-bed restriction and stimulus control may be an issue within the context of general practice.
Online programs based on CBT principles have been proved to be effective in improving the sleep and daytime functioning in this population, but the studies were realized in small patients groups.
Investigators hypothesis is that a simple and internet-delivered short-term program based on sleep restriction therapy and stimulus control (following to a GP consultation) may facilitate hypnotics discontinuation (benzodiazepines/Z-drugs) in patient with insomnia disorder still reporting sleep complaints in comparison with a tapering alone (no access to the self-help program).
Conditions
Interventions
- OTHER
-
Standardized gradual hypnotic taper
The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
- BEHAVIORAL
-
Short-term simple self-help program
The short-term simple self-help program consists in: * Restriction of time in bed * Stimulus control instructions The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program.
Sponsors & Collaborators
-
University Hospital, Bordeaux
lead OTHER
Principal Investigators
-
Antoine BENARD, MD-PhD · USMR - CHU de Bordeaux
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-10-04
- Primary Completion
- 2019-10-25
- Completion
- 2019-11-25
Countries
- France
Study Locations
More Related Trials
-
Brief Intervention for Sleep Medication Misuse Among Elderly
NCT06032715 ·Status: RECRUITING ·Phase: NA
-
Use of Blinded Tapering for Hypnotic Discontinuation
NCT04050176 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy of Sleeping Without Pills (SWOP), an Online Drug Tapering Program
NCT03194802 ·Status: COMPLETED ·Phase: NA
-
Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance
NCT02820441 ·Status: TERMINATED ·Phase: PHASE4
-
Non-pharmacological Treatment of Insomnia in Nursing Homes.
NCT01091987 ·Status: COMPLETED ·Phase: NA
-
Hypnotic Intake and Motor and Cognitive Performances at High Altitude
NCT02778659 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Chronic Hypnotic Use 2
NCT02456532 ·Status: COMPLETED ·Phase: PHASE4
-
Non-pharmacological Treatments for Parasomnias
NCT05953207 ·Status: UNKNOWN ·Phase: NA
-
Sleep Without Insomnia or The Use of Chronic Hypnotics
NCT03687086 ·Status: COMPLETED ·Phase: NA
-
Behavioral and Pharmacological Treatment for Insomnia
NCT00042146 ·Status: COMPLETED ·Phase: PHASE4
-
Cognitive-Behavioural and Hypnotic Treatment of Chronic Primary Insomnia Among the Elderly
NCT00295386 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Chronic Hypnotic Use
NCT01006525 ·Status: COMPLETED
-
Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons
NCT00707915 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia
NCT05233761 ·Status: COMPLETED ·Phase: PHASE2
-
Hypnotic Medications and Memory: Effect of Drug Exposure During the Night
NCT01159652 ·Status: COMPLETED ·Phase: PHASE4
-
Insomnia Behavioral Intervention Study
NCT05301543 ·Status: RECRUITING ·Phase: NA
-
Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and Women
NCT00940550 ·Status: COMPLETED ·Phase: PHASE1
-
Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
NCT01430754 ·Status: COMPLETED ·Phase: PHASE3
-
Reducing Suicidal Ideation Through Insomnia Treatment
NCT01689909 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease
NCT02940912 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia
NCT00466193 ·Status: COMPLETED ·Phase: PHASE3
-
SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.
NCT03331042 ·Status: COMPLETED ·Phase: PHASE3
-
Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
NCT00283790 ·Status: COMPLETED ·Phase: PHASE4
-
Prevention of Delirium in Intensive Care by Melatonin
NCT03524937 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia
NCT00492232 ·Status: COMPLETED ·Phase: PHASE4